DE KLEIJN ED, DE GROOT R, LAFEBER AB, LABADIE J, VAN LIMPT CJ, VISSER CJ, BERBERS GA, VAN ALPHEN L, RUMKE HC; Interscience Conference on Antimicrobial Agents and Chemotherapy.
Abstr Intersci Conf Antimicrob Agents Chemother Intersci Conf Antimicrob Agents Chemother. 2000 Sep 17-20; 40: 249.
Sophia Childrens Hosp., Rotterdam, The Netherlands
Objectives: To study serum bactericidal activity (SBA) against different serogroup B meningococcal strains, 2.5 years after hexavalent RIVM meningococcal OMV vaccination or Hepatitis B vaccination (HBV) and response to booster vaccination.METHODS: Participants in a prior study[1] with RIVM hexavalent meningococcal outer membrane vesicle (OMV) vaccine were revaccinated after 2.5 years with a monovalent P1.7[h],4 meningococcal OMV vaccine. Blood samples were taken before and 4-6 weeks after the booster vaccination. Sera were tested for SBA against six meningococcal strains expressing serosubtypes P1.7[h],4; P1.7,16; P1.5,2; P1.5[c],10; P1.12,13; P1.19,15 and H1.5 (without class 1 OMP).RESULTS: 177 children previously vaccinated with low (n=72) or high (n=59) dose hexavalent meningococcal OMV vaccine or HBV (n=46), were (re)vaccinated with monovalent meningococcal OMV vaccine. In the prevaccination sera, SBA against serosubtype P1.5[c],10 and P1.5,2 were significantly higher in the hexavalent meningococcal vaccine group than in the HBV group (p<0.01). After monovalent P1.7[h],4 meningococcal OMV vaccine, 48.5% of the children in the hexavalent meningococcal group and 8.9% in the HBV group showed at least a fourfold increase in SBA against serosubtype P1.7[h],4. The percentage of children with at least a fourfold increase in SBA against the other serosubtypes varied in the hexavalent vaccine group between 11% and 43%, in the HBV group between 0% and 6.7%. There was no increase in SBA against the control strain H1.5.CONCLUSIONS: SBA against strains with serosubtype P1.5[c],10 and P1.5,2 could still be detected 2.5 years after vaccination with the hexavalent meningococcal vaccine. Boosting with monovalent P1.7[h],4 meningococcal OMV vaccine resulted in significant increase of SBA against P1.7[h],4 and cross reactivity against P1.12,13; P1.5c,10; P1.5,2; P1.19,15 and P1.7,16. SBA is class 1 OMP dependent. 1. de Kleijn, E., de Groot R., Labadie J., Lafeber A., van den Dobbelsteen G., van Alphen L., van Dijken H., Kuipers B., van Omme G., Wala M., Juttmann R. and Rumke H. Immunogenicity and safety of a hexavalent meningococcal outer-membrane-vesicle vaccine in children 2-3 and 7-8 years of age. Vaccine 2000;18(15):1456-1466.KEYWORDS: Immunology; Neisseria meningitidis; OMV vaccine
Publication Types:
Keywords:
- Antibodies
- Antibodies, Bacterial
- Antigens, Bacterial
- Child
- Humans
- Immunization, Secondary
- Immunoglobulin G
- Immunologic Memory
- Meningococcal Infections
- Meningococcal Vaccines
- Neisseria meningitidis
- Vaccination
- immunology
Other ID:
UI: 102249054
From Meeting Abstracts